Navigation Links
Biota makes major antiviral discovery

Biota Holdings Limited announced today that it has discovered a new class of orally-effective, potent antivirals against RSV (respiratory syncytial virus) infection. Biota has filed worldwide patents and selected a lead candidate with a series of backups for further preclinical development prior to human clinical trials.

RSV infection is an important medical need and already a billion-dollar market, with growing visibility among pharmaceutical companies. The currently marketed drug is an injectable antibody with 2004 sales of approximately US$1 billion ($1.3 billion). However, its use is limited to prevention of infection, not treatment, and it is currently only approved for use in the highest risk group of patients: premature infants. If successful, the Biota RSV drug is expected to have significant advantages and could expand the market to include treatment as well as prevention and to other 'at risk' patient segments, such as children, the elderly and people with underlying respiratory conditions.

Latest results in two animal models also demonstrate that Biota's new RSV antivirals are effective when administered orally. This should allow the product to be developed in a convenient oral formulation, such as a tablet or suspension.

"The discovery of a novel, orally available RSV antiviral is a major achievement," said Dr Simon Tucker, Vice President of Research for Biota. "Others, including several large pharmaceutical companies, have discovered and disclosed RSV antivirals, but many are inhaled products. Orally effective RSV compounds appear to be a rarity. This is an exciting achievement for Biota and Australian research."

The current compounds are the result of research conducted by the Biota team over several years. Since 2003, this research has been supported by a $2.7m R&D Start grant from the Australian government. The RSV development follows on the heels of the company's recent decision to advance its common cold (human rh inovirus, HRV) drug candidate into clinical development following a similarly successful in-house research program.


'"/>

Source:Biota


Related biology news :

1. University of Manchester makes made-to-measure skin and bones a reality using inkjet printers
2. Grass makes environmentally friendly biofuel
3. Shampoo detergent added to paint makes surfaces self-sterilizing
4. Green diesel: New process makes liquid transportation fuel from plants
5. Discovery that bacterium is phosphate gourmet key clue to what makes it most social of bacteria
6. Technique makes it easier to see mouse embryo in all its glory
7. In the minds eye: How the brain makes a whole out of parts
8. African parasite makes component of fat differently from all other organisms
9. Coffee makes us more likely to say yes
10. Eat less, weigh more? Enzyme makes lean mice susceptible to dietary fat
11. Embryonic patterning makes the feathers fly
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/26/2016)... 27, 2016 Research and ... Biometrics Market 2016-2020"  report to their offering.  , ... The analysts forecast the global multimodal biometrics ... during the period 2016-2020.  Multimodal biometrics ... such as the healthcare, BFSI, transportation, automotive, and ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... 2016 , ... Researchers at the Universita Politecnica delle Marche in Ancona combed ... pleural mesothelioma. Their findings are the subject of a new article on the Surviving ... signposts in the blood, lung fluid or tissue of mesothelioma patients that can help ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... HOUSTON , June 23, 2016 ... agreement with the Cy-Fair Sports Association to serve ... of the agreement, Houston Methodist Willowbrook will provide ... education and connectivity with association coaches, volunteers, athletes ... partner with the Cy-Fair Sports Association and to ...
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
Breaking Biology Technology: